Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Ipilimumab/nivolumab

Acquired resistance

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Liu D, et al. Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance. Journal of Clinical Oncology 36 (Suppl. 15): abstr. 9581, May 2018. Available from: URL: https://doi.org/10.1200/JCO.2018.36.15_suppl.9581 [abstract] Liu D, et al. Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance. Journal of Clinical Oncology 36 (Suppl. 15): abstr. 9581, May 2018. Available from: URL: https://​doi.​org/​10.​1200/​JCO.​2018.​36.​15_​suppl.​9581 [abstract]
Metadaten
Titel
Ipilimumab/nivolumab
Acquired resistance
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58234-8

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Antineoplastics

Case report

Olaparib

Case report

Perampanel